{"name":"Allogene Therapeutics","slug":"allogene","ticker":"ALLO","exchange":"NASDAQ","domain":"allogene.com","description":"Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"David Chang, M.D., Ph.D.","sector":"Cell Therapy / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$750M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":150152000,"netIncome":-190886000,"cash":51688000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ALLO-501 patent cliff ($0.0B at risk)","drug":"ALLO-501","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"ALLO-715 patent cliff ($0.0B at risk)","drug":"ALLO-715","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Allogene Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $143.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Allogene Therapeutics Announces Collaboration with Servier to Develop and Commercialize ALLO-501A","summary":"Allogene Therapeutics announced a collaboration with Servier to develop and commercialize ALLO-501A, a CAR-T cell therapy for the treatment of relapsed or refractory non-Hodgkin lymphoma.","drugName":"","sentiment":"positive"},{"date":"2023-09-25","type":"trial","headline":"Allogene Therapeutics Announces Update on ALLO-501A Phase 1 Clinical Trial","summary":"Allogene Therapeutics announced an update on its Phase 1 clinical trial of ALLO-501A, with preliminary data showing promising efficacy and safety.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZklZNXBBSi1YalNSSHVTTU9UaEFqZmtjUS1ybUliaG1RUXp0bEQtX1ZuVEN3c0RMY0ZIUlJGR0lzMldWZWZlUGhQTlVRcEgzTGFaQWw5cTFQTmVEQzF2bFVBY3luMU5fa0FuQjNyR2V0WXFZNjFpQ21DTmh5YmxKZ0RKMW1mNHlJcjdoZXBNUWpDcll1T2d0elpoY2NQZDNkeUVJQVY3cjluYnhHN3MyUkM0REJxUkZlQ2hr?oc=5","date":"2026-02-11","type":"trial","source":"Fierce Biotech","summary":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on - Fierce Biotech","headline":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNQnMyenczUk5zWnVLUC15Q29ucHJ1dEZRZkdpS2xrRGlPRklsT1N3c0RjUVgtaDAydmhoRzJidTZWSV92YjhhNGU3djJnSFM3bHc0b2RDWEN0UHQ0UEIySjA3aHVkTEhNem5ieVFzSlVwaW43aHpPWXZDU3MwM1kyWURnWWl6Vk4tR3JKc3ROX1Z1YTMtd3AxVlVpVUt6NWNrc3VVMDljZ2E2UQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Seeking Alpha","summary":"Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha","headline":"Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE00NVU2WkJGVDEzX2N4VHdSZUgwYS0zQnVWSVg5SjM2bTBtSUdNc2ZKanpzdEFqWjhEM0I2OC01SXdGbzNYOU5XYk1JMjN4R0g2SGFV?oc=5","date":"2025-08-01","type":"pipeline","source":"firstwordpharma.com","summary":"Allogene's cell therapy conditioning mAb linked to patient death - firstwordpharma.com","headline":"Allogene's cell therapy conditioning mAb linked to patient death","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOX0NGQ2FtWXRCQkxGQk9LTUZWME5VSkJjVnJHckZ3c0RyckVNTW52dmt5QmNKYXhER3YzQVQ1amFfR2dzdXl5RHNHZjBwVGlCOEVheWJ1RUtvWk43ZGI3dU9hQWZ3MmNlRF9mdkw4bUx4a2t5ZGg3OVZhZjJGd1ltR1NsQW1Uc2NmOWVSMUdUakhrWnZ2dlg3UVREWm50WEZyNmVuVTR5cDVCYkY3dkN3V1RVNlRaM0ZmZ0JoLWJsZlJFZw?oc=5","date":"2025-08-01","type":"trial","source":"Fierce Biotech","summary":"Allogene reports patient death, discontinues investigational antibody in CAR-T pivotal trial - Fierce Biotech","headline":"Allogene reports patient death, discontinues investigational antibody in CAR-T pivotal trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBxSVhMRTlacDNiUktTMmpzR0NkdHZCdk1iY1VZVUtaLXpTaW05RkxIVkpMVDluSkFDYVB4dkJOU0Z3QUZWTnVfVmlROVBGMmFNX004?oc=5","date":"2025-06-02","type":"pipeline","source":"firstwordpharma.com","summary":"ASCO25: CAR-Ts from Allogene, Gilead show early promise in solid tumours - firstwordpharma.com","headline":"ASCO25: CAR-Ts from Allogene, Gilead show early promise in solid tumours","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOem90bXBvV3RyMWlmbVp2X1RCUnc5M3NnalY2SmpTQl90dDZkZ3JjVzQ4VXk3U3lpODc0NGdYbk8xVkNCdTFVWENpN1N2UlNzZHA3WUw3NHA5emIyajJXS1FFaEhJR0w1Ykh2S1VDUmo2WGt3cUVjLUptOVdtYTZzMm12ZERtMmRlczF5TllOQjlrNEY3dmlRalBnbVY1V0hDMmFqNEctalpRWWt6Q0d5djN0cEdjQllpSXpaZ1ZrdDJ1akdiY0F5YWxrM2pWc3c5YkNwREpLNDd5ejh0dlRNbnR5eko3VVNFYXRj0gHwAUFVX3lxTFBzLUJvZmZZNHV5aFJrNjVEanZOT1FWb3M4UWJ6ME13dk1ValppRFFuVXhTSVBCcnpnMzBjVTBDRmF5ZTZTVG1Ja3QybFR5THdGMUo1MHIxX3NEdlF5OWJMMWotandlaXpDZUx6X1VYSlFjQnV0dEJSYTVGa1VucmJFNUFhX0J0dUtLWWd1MC12WHJvTlhzY2tMN1hUMWpYeXg1WDZzbTVQcldnbThIWkhRRVhpYWFGZGxoZkE0RGduMlFYOXRGX1ZjM2pQUkE1RFZoUmRmajVZOHB0dXNTLTlGMmx3NkdQRHhGQktrS3NCbQ?oc=5","date":"2025-05-07","type":"pipeline","source":"simplywall.st","summary":"Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st","headline":"Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may cons","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNZVA5YUhjdHFScVdWZlJfTWpSNndDU081eUFqZEZOU3RSOFl4OWRjR1N0UWlsVDRYd0FvN0NJU2o2bG1CSUdDYTFyRDYwaU9NNUZEdHRzb3VhV2Q2VUpsMGhUWFRyV3JFWFRYZzFpem9ZbVIySzQ4dWtKMjZKQkxyeDFjSUptb2lfWnc?oc=5","date":"2025-02-15","type":"pipeline","source":"The Pharma Letter","summary":"Allogene leaps on allogeneic CAR-T therapy success - The Pharma Letter","headline":"Allogene leaps on allogeneic CAR-T therapy success","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNjlXTHZ0RUpMR2hqZ1J5VHhCdTc1TkhxZlNlVW5wMzNqQ1BYbVBZSzh2WThoOFdOcVJ0WEhjcjRRNmlXMjgxSHVCQVpWN0d5c29vamJaLTAzVUVqbG5jOEJfczNnS0d2NFhubXB0Mm5FT2hjRjNPakZXVkpvRnZ0ZlYwVEdPVnFGWFhCY2FBZ0dyc2FGMHZWc2NNNmQ1M0EtVnl0VUJlSFZ5a3dKUi1vX3dPb1M4N3ZlMElsZER6eE56UQ?oc=5","date":"2024-12-12","type":"pipeline","source":"Allogene","summary":"Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Allogene","headline":"Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNaUs1dFo5SDhFMkgwN2YwY2t3OXBxazZkaXEtbVFtSk55eVNGWFh2ZkFvNFV4OTVSSGtoeEtXTVQ1SjViQW8xc0lnWU9xaUJqTEUzQ2Y5bmlBeTlWc2xHcGp0OXFJeGxGTUFIOWZxcjhJZ0ZWTFMxZGplRHZpMjZMLUF6cVF5YXBxTk15Y3dnbl9hNFVub2I1R0hwcnlkbEFTbV9tTHh3aUVld2JWRFlsdUctdDQzSVlwUWdoNg?oc=5","date":"2023-04-20","type":"pipeline","source":"Allogene","summary":"Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer - Allogene","headline":"Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNTTBjRWFnbEI4NWNqQUdnOFRMX1c1MUlSdEdheVdQN01vbEd2aG5WaFRqT0IwOWRoR1EwME5vSnJaLTBzTDR5QUFuc3J0ak1XbTNZSnF6NTdXTWdRN285UzVLYkFNdzNFQnJPclk5TlJud3N0dURCa01OaU85bU1ic0NzdFhHak8tMFZZZ2g5YXowbDY2NkRPekFXeHB3WFFFaE5ja21nX3ZDYVNpMDNxZVluNA?oc=5","date":"2021-10-08","type":"regulatory","source":"drugdiscoverytrends.com","summary":"Allogene Therapeutics’ stock drops 46% after FDA puts hold on AlloCAR-T trials - drugdiscoverytrends.com","headline":"Allogene Therapeutics’ stock drops 46% after FDA puts hold on AlloCAR-T trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPVzBjZENKZnJoRGZmV21iRllhUU1ObXRrblZRZDljTjhTOEJTalRpMDlKYWlLR0pmNTVjWnNQeEhzVTh4eWpZQlp4WjltZXZndm9NNnZ3R2ZOZGhCR3lKMnJHRjJ5Y3FiSDMyX0NNM2YtVHA4M3lVcGtvTnM0eTB3LQ?oc=5","date":"2021-10-07","type":"regulatory","source":"BioPharma Dive","summary":"Allogene cell therapy trials halted by FDA after unexpected safety finding - BioPharma Dive","headline":"Allogene cell therapy trials halted by FDA after unexpected safety finding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOMUt1Z3J0Qnc2OWxDYVY2cmtLT19FazRKcnNFTkllOUZoWVM0UkowTUt0S09jWUJaWkw4R3hIX2tUMWRLSEEtZGQxdGFDN0duS3VqcDk5cnJONkJud18tOFV4SkpDUFZVbjlvOXI0eE5DQ3BBMTR0bnNXMDM1eHZJTGtKd09Sc0N3dm1qYTM2cEVKaFljaV9MVjlzZnl2NlVBbThiVFRyT2dfQi1mMXlUWDdZRDBLdWF6RzhLeU5POTI4RzNLcklrTnktQQ?oc=5","date":"2021-06-21","type":"pipeline","source":"Business Wire","summary":"Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer - Business Wire","headline":"Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer","sentiment":"neutral"}],"patents":[{"drugName":"ALLO-501","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"ALLO-715","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Gilead Sciences","Janssen Pharmaceuticals"],"therapeuticFocus":["Oncology","Cell Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":22000,"period":"2024-12-31"},{"value":95000,"period":"2023-12-31"},{"value":74000,"period":"2023-09-30"},{"value":52000,"period":"2023-06-30"},{"value":30000,"period":"2023-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":150152000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-190886000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":51688000,"cashHistory":[],"totalAssets":415905000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}